Last reviewed · How we verify
FS-1502
At a glance
| Generic name | FS-1502 |
|---|---|
| Sponsor | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. (PHASE1)
- FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FS-1502 CI brief — competitive landscape report
- FS-1502 updates RSS · CI watch RSS
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. portfolio CI